foxo4 dri senolytic or senomorphic FOXO4-DRI Dosing: 1mg Protocol (2026) Cleara Biotech senolytic candidate FOXO4-DRI
Cleara Biotech senolytic candidate FOXO4 DRI The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Frontiers Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS
Pay in 4 interest-free payments of $5.76 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



